Log in

NASDAQ:KALAKala Pharmaceuticals Stock Price, Forecast & News

$10.56
-0.09 (-0.85 %)
(As of 07/3/2020 04:00 PM ET)
Add
Compare
Today's Range
$10.31
Now: $10.56
$10.98
50-Day Range
$10.26
MA: $12.43
$13.79
52-Week Range
$3.24
Now: $10.56
$14.68
Volume589,339 shs
Average Volume1.12 million shs
Market Capitalization$576.26 million
P/E RatioN/A
Dividend YieldN/A
Beta0.34
Kala Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies using its proprietary nanoparticle-based Mucus Penetrating Particles (MPP) technology for the treatment of eye diseases. The company's lead product candidate is KPI-121 0.25% which has completed two Phase III clinical trials for the treatment of temporary relief of the signs and symptoms of dry eye disease; INVELTYS which has completed two Phase III clinical trials for the treatment of inflammation and pain following ocular surgery; and KPI-285, a MPP receptor tyrosine kinase inhibitor program, which is in preclinical studies for the treatment of retinal diseases. The company was formerly known as Hanes Newco, Inc. and changed its name to Kala Pharmaceuticals, Inc. in December 2009. Kala Pharmaceuticals, Inc. was founded in 2009 and is headquartered in Watertown, Massachusetts.
Read More
Kala Pharmaceuticals logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.55 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:KALA
CUSIPN/A
Phone781-996-5252

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$6.07 million
Book Value$0.86 per share

Profitability

Net Income$-94,350,000.00
Net Margins-1,578.64%

Miscellaneous

Employees136
Market Cap$576.26 million
Next Earnings Date8/4/2020 (Estimated)
OptionableOptionable

Receive KALA News and Ratings via Email

Sign-up to receive the latest news and ratings for KALA and its competitors with MarketBeat's FREE daily newsletter.

Kala Pharmaceuticals (NASDAQ:KALA) Frequently Asked Questions

How has Kala Pharmaceuticals' stock been impacted by COVID-19 (Coronavirus)?

Kala Pharmaceuticals' stock was trading at $7.63 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, KALA shares have increased by 38.4% and is now trading at $10.56. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Kala Pharmaceuticals?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Kala Pharmaceuticals in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Kala Pharmaceuticals.

When is Kala Pharmaceuticals' next earnings date?

Kala Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Tuesday, August 4th 2020. View our earnings forecast for Kala Pharmaceuticals.

How were Kala Pharmaceuticals' earnings last quarter?

Kala Pharmaceuticals Inc (NASDAQ:KALA) issued its quarterly earnings results on Thursday, May, 7th. The company reported ($0.54) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.51) by $0.03. The company had revenue of $1.07 million for the quarter, compared to analyst estimates of $2.49 million. Kala Pharmaceuticals had a negative return on equity of 132.08% and a negative net margin of 1,578.64%. View Kala Pharmaceuticals' earnings history.

What price target have analysts set for KALA?

5 brokerages have issued 12-month price objectives for Kala Pharmaceuticals' stock. Their forecasts range from $15.00 to $39.00. On average, they anticipate Kala Pharmaceuticals' share price to reach $22.20 in the next year. This suggests a possible upside of 110.2% from the stock's current price. View analysts' price targets for Kala Pharmaceuticals.

Has Kala Pharmaceuticals been receiving favorable news coverage?

News coverage about KALA stock has trended negative on Sunday, according to InfoTrie Sentiment. The research firm identifies positive and negative media coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Kala Pharmaceuticals earned a media sentiment score of -2.4 on InfoTrie's scale. They also gave news headlines about the company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an impact on the company's share price in the near term. View the latest news about Kala Pharmaceuticals.

Who are some of Kala Pharmaceuticals' key competitors?

What other stocks do shareholders of Kala Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Kala Pharmaceuticals investors own include Bristol-Myers Squibb (BMY), Amarin (AMRN), Alibaba Group (BABA), Clovis Oncology (CLVS), Micron Technology (MU), NVIDIA (NVDA), AbbVie (ABBV), Gilead Sciences (GILD), Verastem (VSTM) and Inovio Pharmaceuticals (INO).

Who are Kala Pharmaceuticals' key executives?

Kala Pharmaceuticals' management team includes the following people:
  • Mr. Mark T. Iwicki, Chairman, Pres & CEO (Age 54, Pay $871.14k)
  • Mr. Todd Bazemore, Chief Operating Officer (Age 50, Pay $607.5k)
  • Mr. Eric L. Trachtenberg, Gen. Counsel, Chief Compliance Officer & Corp. Sec. (Age 47, Pay $646.56k)
  • Dr. Justin Hanes Ph.D., Founder & Chair of the Scientific Advisory Board
  • Ms. Mary Reumuth CPA, CPA, CFO & Treasurer (Age 45)

When did Kala Pharmaceuticals IPO?

(KALA) raised $90 million in an IPO on Thursday, July 20th 2017. The company issued 6,000,000 shares at $14.00-$16.00 per share. J.P. Morgan and BofA Merrill Lynch acted as the underwriters for the IPO and Wells Fargo Securities and Wedbush PacGrow were co-managers.

What is Kala Pharmaceuticals' stock symbol?

Kala Pharmaceuticals trades on the NASDAQ under the ticker symbol "KALA."

How do I buy shares of Kala Pharmaceuticals?

Shares of KALA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Kala Pharmaceuticals' stock price today?

One share of KALA stock can currently be purchased for approximately $10.56.

How big of a company is Kala Pharmaceuticals?

Kala Pharmaceuticals has a market capitalization of $576.26 million and generates $6.07 million in revenue each year. The company earns $-94,350,000.00 in net income (profit) each year or ($2.76) on an earnings per share basis. Kala Pharmaceuticals employs 136 workers across the globe.

What is Kala Pharmaceuticals' official website?

The official website for Kala Pharmaceuticals is www.kalarx.com.

How can I contact Kala Pharmaceuticals?

Kala Pharmaceuticals' mailing address is 490 ARSENAL WAY SUITE 120, WALTHAM MA, 02472. The company can be reached via phone at 781-996-5252 or via email at [email protected]

This page was last updated on 7/5/2020 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools:

  • Best-in-Class Portfolio Monitoring

    View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.

  • Stock Ideas and Recommendations

    Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.

  • Advanced Stock Screeners and Research Tools

    Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.